HK1244668A1 - 用於治療丙型肝炎的兩種抗病毒劑的組合 - Google Patents

用於治療丙型肝炎的兩種抗病毒劑的組合

Info

Publication number: HK1244668A1
Authority: HK; Hong Kong
Prior art keywords: hepatitis; treatment; combination; antiviral agents; antiviral
Prior art date: 2013-03-14

Application number

HK18103210.8A

Other languages

English (en)

Inventor

Barry M Bernstein

Sandeep Dutta

Wei Liu

Thomas J Podsadecki

Andrew L Campbell

Rajeev M Menon

Chih-Wei Lin

Tianli Wang

Walid M Awni

Sven Mensing

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-14

Filing date

2016-07-20

Publication date

2018-08-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1244668(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-07-20 Application filed by Abbvie Inc filed Critical Abbvie Inc

2018-08-17 Publication of HK1244668A1 publication Critical patent/HK1244668A1/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

HK18103210.8A 2013-03-14 2016-07-20 用於治療丙型肝炎的兩種抗病毒劑的組合 HK1244668A1 (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361783376P	2013-03-14	2013-03-14

Publications (1)

Publication Number	Publication Date
HK1244668A1 true HK1244668A1 (zh)	2018-08-17

Family

ID=50588882

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK16108631.0A HK1223817A1 (zh)	2013-03-14	2016-07-20	用於治療丙型肝炎的兩種抗病毒劑的組合
HK18103210.8A HK1244668A1 (zh)	2013-03-14	2016-07-20	用於治療丙型肝炎的兩種抗病毒劑的組合

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK16108631.0A HK1223817A1 (zh)	2013-03-14	2016-07-20	用於治療丙型肝炎的兩種抗病毒劑的組合

Country Status (26)

Country	Link
US (1)	US20140275099A1 (zh)
EP (3)	EP3766495A1 (zh)
JP (4)	JP6441303B2 (zh)
KR (2)	KR20210013344A (zh)
CN (2)	CN105073113B (zh)
AU (2)	AU2014239563B2 (zh)
BR (1)	BR112015023017B1 (zh)
CA (1)	CA2901810C (zh)
CY (2)	CY1119025T1 (zh)
DK (2)	DK2968301T3 (zh)
EA (2)	EA033257B1 (zh)
ES (2)	ES2824473T3 (zh)
HK (2)	HK1223817A1 (zh)
HR (2)	HRP20171036T1 (zh)
HU (2)	HUE052113T2 (zh)
IL (1)	IL240419B (zh)
LT (2)	LT3213750T (zh)
MX (3)	MX362616B (zh)
NZ (2)	NZ631155A (zh)
PL (2)	PL3213750T3 (zh)
PT (2)	PT2968301T (zh)
RS (2)	RS60881B1 (zh)
SG (2)	SG11201507364SA (zh)
SI (2)	SI3213750T1 (zh)
TW (2)	TWI686196B (zh)
WO (1)	WO2014152514A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
EP3766495A1 (en)	2013-03-14	2021-01-20	AbbVie Inc.	Combination of two antivirals for treating hepatitis c
WO2017007934A1 (en) *	2015-07-08	2017-01-12	Abbvie Inc.	Methods for treating hcv
WO2015002952A1 (en) *	2013-07-02	2015-01-08	Abbvie Inc.	Methods for treating hcv
CA2925328A1 (en) *	2013-10-25	2015-04-30	Abbvie, Inc.	Methods for treating hcv
US20150174194A1 (en) *	2013-12-19	2015-06-25	Abbvie Inc.	Methods for treating liver transplant recipients
AU2015240754B2 (en) *	2014-04-02	2020-06-25	Abbvie Inc.	Methods for treating HCV
AU2015240753B2 (en) *	2014-04-02	2020-01-16	Abbvie Inc.	Methods for treating HCV
MX2018000218A (es) *	2015-06-26	2018-03-08	Abbvie Inc	Composiciones farmaceuticas solidas para el tratamiento del vhc.
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
US20230385268A1 (en) *	2022-05-17	2023-11-30	Abbvie Inc.	Methods for Treating HCV
EA201890334A1 (ru) *	2015-07-17	2018-06-29	Эббви Инк.	Твердые фармацевтические композиции для лечения вируса гепатита с
CN109689063A (zh)	2016-04-28	2019-04-26	埃默里大学	含有炔烃的核苷酸和核苷治疗组合物及其相关用途
US20180085330A1 (en) *	2016-09-23	2018-03-29	Abbvie Inc.	Dose Adjustment
CA2994496A1 (en) *	2017-02-14	2018-08-14	Abbvie Inc.	Methods for treating hcv
CA2981993A1 (en) *	2017-08-02	2019-02-02	Abbvie Inc.	Methods for treating hcv
KR20200140865A (ko) *	2018-04-10	2020-12-16	아테아 파마슈티컬즈, 인크.	간경변증을 갖는 hcv 감염 환자의 치료
AU2019384793A1 (en)	2018-11-20	2021-06-10	Abbvie Inc.	Methods for treating acute HCV
KR102077833B1 (ko)	2018-12-10	2020-02-14	류형준	기능성 식품조성물
CN111688355B (zh)	2019-03-15	2022-04-12	精工爱普生株式会社	液体吸收体、液体吸收器以及液体喷出装置
JP2020172484A (ja) *	2019-04-08	2020-10-22	アッヴィ・インコーポレイテッド	Ｈｃｖを治療するための固体医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9394279B2 (en)	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
US8937150B2 (en) *	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
NZ608720A (en)	2010-09-21	2015-03-27	Enanta Pharm Inc	Macrocyclic proline derived hcv serine protease inhibitors
US8330139B2 (en)	2011-03-25	2012-12-11	Micron Technology, Inc.	Multi-level memory cell
ES2527544T1 (es)	2011-10-21	2015-01-26	Abbvie Inc.	Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
EP2583677A3 (en)	2011-10-21	2013-07-03	Abbvie Inc.	Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
DK2897611T3 (da) *	2012-09-18	2019-11-04	Abbvie Inc	Fremgangsmåder til behandling af hepatitis c
EP3766495A1 (en)	2013-03-14	2021-01-20	AbbVie Inc.	Combination of two antivirals for treating hepatitis c

2014
- 2014-03-14 EP EP20183791.1A patent/EP3766495A1/en active Pending
- 2014-03-14 PT PT147199772T patent/PT2968301T/pt unknown
- 2014-03-14 CN CN201480015311.3A patent/CN105073113B/zh not_active Expired - Fee Related
- 2014-03-14 PL PL17165207T patent/PL3213750T3/pl unknown
- 2014-03-14 LT LTEP17165207.6T patent/LT3213750T/lt unknown
- 2014-03-14 EA EA201591702A patent/EA033257B1/ru unknown
- 2014-03-14 HU HUE17165207A patent/HUE052113T2/hu unknown
- 2014-03-14 SG SG11201507364SA patent/SG11201507364SA/en unknown
- 2014-03-14 SI SI201431674T patent/SI3213750T1/sl unknown
- 2014-03-14 JP JP2016502431A patent/JP6441303B2/ja active Active
- 2014-03-14 ES ES17165207T patent/ES2824473T3/es active Active
- 2014-03-14 ES ES14719977.2T patent/ES2624980T3/es active Active
- 2014-03-14 RS RS20201198A patent/RS60881B1/sr unknown
- 2014-03-14 TW TW107108651A patent/TWI686196B/zh not_active IP Right Cessation
- 2014-03-14 EP EP14719977.2A patent/EP2968301B1/en not_active Revoked
- 2014-03-14 RS RS20170672A patent/RS56202B1/sr unknown
- 2014-03-14 KR KR1020217002760A patent/KR20210013344A/ko active Pending
- 2014-03-14 SI SI201430265A patent/SI2968301T1/sl unknown
- 2014-03-14 PL PL14719977T patent/PL2968301T3/pl unknown
- 2014-03-14 DK DK14719977.2T patent/DK2968301T3/en active
- 2014-03-14 NZ NZ631155A patent/NZ631155A/en unknown
- 2014-03-14 CA CA2901810A patent/CA2901810C/en active Active
- 2014-03-14 MX MX2015012538A patent/MX362616B/es active IP Right Grant
- 2014-03-14 AU AU2014239563A patent/AU2014239563B2/en active Active
- 2014-03-14 DK DK17165207.6T patent/DK3213750T3/da active
- 2014-03-14 SG SG10201708306WA patent/SG10201708306WA/en unknown
- 2014-03-14 BR BR112015023017-2A patent/BR112015023017B1/pt active IP Right Grant
- 2014-03-14 CN CN201810067970.1A patent/CN108159393A/zh active Pending
- 2014-03-14 TW TW103109530A patent/TWI642436B/zh not_active IP Right Cessation
- 2014-03-14 US US14/210,870 patent/US20140275099A1/en not_active Abandoned
- 2014-03-14 PT PT171652076T patent/PT3213750T/pt unknown
- 2014-03-14 WO PCT/US2014/027423 patent/WO2014152514A1/en active Application Filing
- 2014-03-14 KR KR1020157029549A patent/KR102210935B1/ko active Active
- 2014-03-14 HU HUE14719977A patent/HUE033010T2/en unknown
- 2014-03-14 NZ NZ719137A patent/NZ719137A/en unknown
- 2014-03-14 MX MX2018008084A patent/MX373314B/es unknown
- 2014-03-14 EP EP17165207.6A patent/EP3213750B1/en active Active
- 2014-03-14 EA EA201991174A patent/EA201991174A1/ru unknown
- 2014-03-14 LT LTEP14719977.2T patent/LT2968301T/lt unknown
2015
- 2015-08-06 IL IL240419A patent/IL240419B/en active IP Right Grant
- 2015-09-11 MX MX2020005054A patent/MX2020005054A/es unknown
2016
- 2016-05-03 AU AU2016202823A patent/AU2016202823B2/en active Active
- 2016-07-20 HK HK16108631.0A patent/HK1223817A1/zh unknown
- 2016-07-20 HK HK18103210.8A patent/HK1244668A1/zh unknown
2017
- 2017-06-21 CY CY20171100653T patent/CY1119025T1/el unknown
- 2017-07-06 HR HRP20171036TT patent/HRP20171036T1/hr unknown
2018
- 2018-11-22 JP JP2018219054A patent/JP6621902B2/ja active Active
2019
- 2019-11-19 JP JP2019208502A patent/JP2020037589A/ja active Pending
2020
- 2020-10-05 HR HRP20201575TT patent/HRP20201575T1/hr unknown
- 2020-10-05 CY CY20201100930T patent/CY1123387T1/el unknown
2021
- 2021-06-07 JP JP2021094935A patent/JP2021130720A/ja active Pending

Also Published As

Publication number	Publication date
MX362616B (es)	2019-01-28
LT2968301T (lt)	2017-05-25
CN108159393A (zh)	2018-06-15
MX2015012538A (es)	2016-02-10
MX2020005054A (es)	2020-08-20
PT3213750T (pt)	2020-10-19
US20140275099A1 (en)	2014-09-18
KR20210013344A (ko)	2021-02-03
EP2968301A1 (en)	2016-01-20
JP6621902B2 (ja)	2019-12-18
HUE052113T2 (hu)	2021-04-28
KR102210935B1 (ko)	2021-02-02
BR112015023017B1 (pt)	2022-08-30
EA201591702A1 (ru)	2016-09-30
SI2968301T1 (sl)	2017-07-31
CA2901810A1 (en)	2014-09-25
JP2020037589A (ja)	2020-03-12
JP6441303B2 (ja)	2018-12-19
IL240419A0 (en)	2015-09-24
WO2014152514A1 (en)	2014-09-25
CY1119025T1 (el)	2018-01-10
EP3213750A1 (en)	2017-09-06
EP2968301B1 (en)	2017-04-19
RS60881B1 (sr)	2020-11-30
ES2624980T3 (es)	2017-07-18
PL2968301T3 (pl)	2017-09-29
TWI686196B (zh)	2020-03-01
CA2901810C (en)	2019-01-08
NZ719137A (en)	2017-11-24
EA201991174A1 (ru)	2020-01-31
SG11201507364SA (en)	2015-10-29
HUE033010T2 (en)	2017-11-28
DK3213750T3 (da)	2020-10-19
CN105073113B (zh)	2018-01-02
TW201511759A (zh)	2015-04-01
HRP20201575T1 (hr)	2020-12-11
EP3766495A1 (en)	2021-01-20
JP2019048868A (ja)	2019-03-28
SI3213750T1 (sl)	2020-11-30
BR112015023017A2 (pt)	2017-07-18
RS56202B1 (sr)	2017-11-30
AU2016202823A1 (en)	2016-05-19
TWI642436B (zh)	2018-12-01
IL240419B (en)	2019-03-31
AU2014239563B2 (en)	2016-05-05
EP3213750B1 (en)	2020-08-12
AU2016202823B2 (en)	2017-11-23
EA033257B1 (ru)	2019-09-30
HK1223817A1 (zh)	2017-08-11
MX373314B (es)	2025-03-05
SG10201708306WA (en)	2017-11-29
LT3213750T (lt)	2020-10-26
PL3213750T3 (pl)	2020-12-14
AU2014239563A1 (en)	2015-08-27
CY1123387T1 (el)	2021-12-31
NZ631155A (en)	2016-05-27
TW201834656A (zh)	2018-10-01
HRP20171036T1 (hr)	2017-10-06
PT2968301T (pt)	2017-07-17
DK2968301T3 (en)	2017-07-24
JP2021130720A (ja)	2021-09-09
ES2824473T3 (es)	2021-05-12
CN105073113A (zh)	2015-11-18
JP2016513695A (ja)	2016-05-16
KR20150129032A (ko)	2015-11-18

Publication	Publication Date	Title
HK1244668A1 (zh)	2018-08-17	用於治療丙型肝炎的兩種抗病毒劑的組合
HRP20181679T1 (hr)	2018-12-14	Amidni spojevi za liječenje hiv
LT3121164T (lt)	2020-08-10	Sulfamoilpirolamido dariniai ir jų panaudojimas kaip vaistų hepatito b gydymui
DK3033086T3 (da)	2022-01-03	Kombinationsterapi til behandling af cancer
DK2968208T3 (da)	2022-08-22	Behandling af kataplexi
DK2981255T3 (da)	2022-11-14	Terapeutiske anvendelser af empagliflozin
LT2928477T (lt)	2019-10-10	Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
DK3079748T3 (da)	2020-08-17	Udskylleligt nedbrydningskateter
DK3511004T3 (da)	2024-09-23	Kombineret præparat til behandling af cancer
FI20135231A (fi)	2014-09-12	Potilasalusta
HK1216391A1 (zh)	2016-11-11	組合治療
DK3089778T3 (da)	2019-10-07	Ballonkateter
HUE063095T2 (hu)	2023-12-28	Eljárások pirimidinilciklopentán vegyületek elõállítására
EP2994184C0 (en)	2023-06-07	UNROLLABLE CATHETER
DK2976101T3 (da)	2020-11-23	Behandlingsfremgangsmåde
EP2958454A4 (en)	2016-11-30	MAGNETOTHERAPEUTIC BAND
EP2992915A4 (en)	2016-11-09	MEDICAL HELP
DK3041506T3 (da)	2023-02-27	Behandlingsfremgangsmåde
ES1094985Y (es)	2014-02-26	Mini-moto infantil
FI20136034A (fi)	2014-12-15	Sauna
FI10329U1 (fi)	2013-12-12	Kaasujen käsittelylaitteisto
EP2958932A4 (en)	2016-08-10	THERAPEUTICS
UA27190S (uk)	2014-06-25	Ванна дитяча
TH1501000986A (th)	2016-11-09	ซัลฟาโมอิล-แอริลเอไมด์และการใช้ของสิ่งนั้นเป็นยาสำหรับการบำบัดตับอักเสบ b
BR302013002360S1 (pt)	2014-06-10	Configuração aplicada em carrinho"